https://www.socictopen.socict.org/files/original/ca93a3054406324775343498cc70359e.pdf 533f3a4fda7bb91f70b3382b4366a1f3 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice. Creator An entity primarily responsible for making the resource Shmuel Yitzhaki, Jonathan D Edgeworth, Hagit Achdout, Tal Noy-Porat, Adva Mechaly, Yinon Levy, Efi Makdasi, Ron Alcalay, David Gur, Moshe Aftalion, Reut Falach, Shani Leviatan Ben-Arye, Shirley Lazar, Ayelet Zauberman, Eyal Epstein, Theodor Chitlaru, Shay Weiss, Raghavendra Kikkeri, Hai Yu, Xi Chen, Shmuel C Shapira, Vered Padler-Karavani, Ohad Mazor, Ronit Rosenfeld Description An account of the resource Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion that antibody treatments need to rely on highly neutralizing monoclonal antibodies (mAbs), targeting several distinct epitopes for circumventing therapy escape mutants. Previously, we reported efficient human therapeutic mAbs recognizing epitopes on the spike receptor-binding domain (RBD) of SARS-CoV-2. Here we report the isolation, characterization, and recombinant production of 12 neutralizing human mAbs, targeting three distinct epitopes on the spike N-terminal domain of the virus. Neutralization mechanism of these antibodies involves receptors other than the canonical hACE2 on target cells, relying both on amino acid and N-glycan epitope recognition, suggesting alternative viral cellular portals. Two selected mAbs demonstrated full protection of K18-hACE2 transgenic mice when administered at low doses and late post-exposure, demonstrating the high potential of the mAbs for therapy of SARS-CoV-2 infection. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource virology, molecular biology, Immunology Identifier An unambiguous reference to the resource within a given context 10.1016/j.isci.2021.102479 Source A related resource from which the described resource is derived iScience